Immunocore fills melanoma trial and Immunocore stock sits 25.00 percent below high

Published on 10/02/2026 at 04:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Immunocore enrolled 540 TEBE-AM patients on September 14, 2026. Immunocore stock reflects USD 115.9 million KIMMTRAK revenue in the second quarter of 2026.

IMCR, US45258D1054, Illustration mit AI erstellt.

Immunocore (US45258D1054) enrolled 540 patients in its Phase 3 TEBE-AM melanoma trial on September 14, 2026, while its latest Nasdaq quote stood 25.00 percent below the 52-week high. The trial reached its target enrollment for tebentafusp, also known as KIMMTRAK, in previously treated advanced melanoma.

Trial enrollment reaches 540 patients

According to Immunocore in its September 14, 2026 filing, the registrational study is evaluating tebentafusp alone and in combination with pembrolizumab against investigator's choice. The study's primary endpoint is overall survival, and the company expects topline data as early as the end of 2026.

The enrollment milestone matters because TEBE-AM targets patients with HLA-A*02:01-positive unresectable or metastatic melanoma whose disease progressed after prior therapy. It expands the clinical opportunity beyond KIMMTRAK's established use in metastatic uveal melanoma, but the investment case still depends on the survival result rather than enrollment alone.

KIMMTRAK revenue rises 18.00 percent

Immunocore's commercial base supplied a measurable operating counterweight in the second quarter of 2026. StockTitan reported KIMMTRAK net product revenue of USD 115.9 million for the quarter, up 18.00 percent from USD 98.2 million in the second quarter of 2025.

The same filing summary reported USD 12.2 million of net income for the first half of 2026 and USD 880.2 million in cash, cash equivalents and marketable securities as of June 30, 2026. That cash position gives the company room to fund several late-stage programs, while the 2026 rebate accrual of about USD 120 million adds a concrete use of cash to the outlook.

IMCR stays below its yearly high

IMCR had a market capitalization of USD 1.6 billion as of October 1, 2026. Its 52-week range was USD 27.55 to USD 40.72, and the latest Nasdaq quote was USD 30.54 on October 1, 2026 at 4:00 p.m. ET, which is 25.00 percent below the high.